Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies.
Anticancer Agents Med Chem
; 8(8): 863-71, 2008 Dec.
Article
en En
| MEDLINE
| ID: mdl-19075569
ABSTRACT
Cdc25A, a dual specificity protein phosphatase, is well-recognized as a critical regulator for cell cycle progression. We recently found that it also regulates mitogen-activated protein kinase (MAPK) signal transduction pathway. Inhibition of Cdc25A activity by a K vitamin analog Compound 5 (Cpd 5) can induce a strong and prolonged activation of epidermal growth factor receptor (EGFR)-MAPK pathway, which leads to suppression of transcription factors CREB and c-Myc, resulting in decreased expression of Cdc25A and cyclin D1 levels. Our investigations suggest that Cdc25A plays a central role in regulating and linking cell cycle progression and MAPK signal transduction pathways. Several other recently synthesized K vitamin analogs also affect this pathway, including the non-quinone PM20 and fluoro-Cpd 5. Thus, searching for new and efficient small molecules to inhibit Cdc25A activity may provide new means to control cancers of the liver and other sites.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma Hepatocelular
/
Fosfatasas cdc25
/
Inhibidores Enzimáticos
/
Neoplasias Hepáticas
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Anticancer Agents Med Chem
Asunto de la revista:
ANTINEOPLASICOS
/
QUIMICA
Año:
2008
Tipo del documento:
Article
País de afiliación:
Estados Unidos